Royalty Pharma plc
Royalty Pharma plc (RPRX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · RPRX · as of Sep 30, 2025
Ownership Breakdown
499
Institutional Holders
▲ 29 vs Q2
$11.57B
Total Inst. Value
▼ $768.53M vs Q2
430.12M
Shares Outstanding
freeFloat 95.40%
327.87M
13F Shares Held
▼ 14.37M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
RPRX largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
MORGAN STANLEY pharmaceutical preparations | 44.16M | 10.22% | 10.22% | $1.56T | May 27, 2026 | ▼ 2.44M |
FMR LLC pharmaceutical preparations | 27.99M | 6.47% | 6.47% | $987.37B | Nov 13, 2025 | ▼ 12.37M |
CAPITAL INTERNATIONAL INVESTORS pharmaceutical preparations | 27.21M | 6.29% | 6.29% | $960.06B | Nov 13, 2025 | ▲ 5.33M |
BLACKROCK, INC. pharmaceutical preparations | 26.20M | 6.06% | 6.06% | $924.35B | Nov 12, 2025 | ▲ 771.6K |
BAILLIE GIFFORD & CO pharmaceutical preparations | 17.37M | 4.02% | 4.02% | $612.90B | Oct 31, 2025 | ▼ 648.0K |
SWEDBANK AB pharmaceutical preparations | 12.20M | 2.82% | 2.82% | $430.43B | Oct 15, 2025 | ▲ 42.8K |
ADAGE CAPITAL PARTNERS GP, L.L.C. pharmaceutical preparations | 11.97M | 2.77% | 2.77% | $422.15B | Nov 14, 2025 | ▲ 5.97M |
VANGUARD GROUP INC pharmaceutical preparations | 10.94M | 2.53% | 2.53% | $385.84B | Nov 7, 2025 | ▼ 25.44M |
STATE STREET CORP pharmaceutical preparations | 10.27M | 2.38% | 2.38% | $362.42B | Nov 14, 2025 | ▲ 77.8K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 7.62M | 1.76% | 1.76% | $268.03B | Nov 12, 2025 | ▼ 559.1K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
32
Increased
+27.34M shares3
New Positions
first time holders14
Decreased
−44.36M shares0
Sold Out
fully exitedNet shares change (top 50)
17.02M
+27.34M / −44.36M
Net new holders
+21
3 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
RPRX insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
4
Buy transactions
8
Sell transactions
0.50
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Coyne Terrance P. EVP & CFO | May 26, 2026 | Sale | 64,399 | $53.98 | $3.48M | 0 | Form 4 ↗ |
Urist Marshall EVP, Research & Investments | May 20, 2026 | Sale | 13,684 | $52.75 | $721.8K | 18.2K | Form 4 ↗ |
Urist Marshall EVP, Research & Investments | May 14, 2026 | Sale | 13,684 | $53.06 | $726.1K | 31.9K | Form 4 ↗ |
Norden Gregory director | May 14, 2026 | Sale | 3,045 | $53.00 | $161.4K | 191.8K | Form 4 ↗ |
Legorreta Pablo G. CEO, Chairman of the Board | May 6, 2026 | Award | 143,821 | — | — | 1.24M | Form 4 ↗ |
Coyne Terrance P. EVP & CFO | May 6, 2026 | Award | 24,263 | — | — | 64.4K | Form 4 ↗ |
Hite Christopher EVP & Vice Chairman | May 6, 2026 | Award | 24,263 | — | — | 709.4K | Form 4 ↗ |
Urist Marshall EVP, Research & Investments | May 6, 2026 | Award | 18,197 | — | — | 45.6K | Form 4 ↗ |
Coyne Terrance P. EVP & CFO | Apr 28, 2026 | Sale | 1,875 | $49.78 | $93.3K | 40.1K | Form 4 ↗ |
Coyne Terrance P. EVP & CFO | Apr 28, 2026 | Sale | 32,916 | $49.78 | $1.64M | 0 | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Royalty Pharma plc (RPRX) is primarily owned by institutional investors, who hold approximately 76.2% of total shares outstanding. Company insiders own approximately 4.60%, while retail and public investors account for the remaining 19.18%.
The largest institutional shareholder of Royalty Pharma plc is MORGAN STANLEY, holding approximately 44.16 million shares — equal to 10.22% of outstanding shares — as of September 30, 2025.
A total of 499 institutional investors currently hold RPRX stock, with a combined institutional value of approximately $11.57 billion as of the most recent 13F filing period.
Frequently asked questions
RPRX ownershipRoyalty Pharma plc (RPRX) is primarily owned by institutional investors, who hold approximately 76.2% of shares. The largest shareholder is MORGAN STANLEY with a 10.22% stake. Company insiders hold 4.60%. Data sourced from SEC Form 13F as of September 30, 2025.